Humulina Nph Kwikpen

Humulina Nph Kwikpen is a pre‑filled pen containing insulin human (rDNA) for subcutaneous injection. It delivers a neutral protamine Hagedorn (NPH) formulation of human insulin, providing intermediate‑acting glucose‑lowering activity. The product is authorized in the European Union and is available by prescription only. It is designed for patients with diabetes mellitus who require basal insulin support. The pen device allows convenient dosing and reduces need for separate syringes and vials.

Humulina Nph Kwikpen is indicated for the management of blood glucose in adults and children with diabetes mellitus who need basal insulin therapy.

- Provides intermediate‑acting insulin coverage to control fasting glucose levels. - Used as part of a basal‑bolus regimen together with rapid‑acting insulin. - Suitable for patients with type 1 diabetes requiring long‑acting insulin. - Suitable for patients with type 2 diabetes when oral agents are insufficient. - Can be combined with lifestyle measures such as diet and exercise.

Adverse reactions to Humulina Nph Kwikpen may vary in frequency and severity.

Common: - Hypoglycemia (low blood sugar) - Injection‑site pain, redness, or swelling - Lipodystrophy (localized fat tissue changes) - Weight gain

Serious: - Severe hypoglycemia leading to loss of consciousness - Allergic reactions such as rash, urticaria, or anaphylaxis - Hypokalemia (low potassium levels)

When using Humulina Nph Kwikpen, several safety considerations should be observed.

- Monitor blood glucose regularly to avoid hypoglycemia. - Adjust dose during periods of illness, stress, or changes in physical activity. - Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced. - Educate patients on proper injection technique to minimize lipodystrophy. - Pregnant or breastfeeding individuals should consult a healthcare professional before use. - Store the pen according to manufacturer instructions and discard after the indicated period once opened.

Humulina Nph Kwikpen can interact with other medicines, affecting glucose control or insulin action.

Avoid: - Concurrent use of other insulin products without dose adjustment, which may cause severe hypoglycemia. - Beta‑blockers, which can mask hypoglycemia symptoms. - High‑dose corticosteroids, which may increase insulin resistance.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that can potentiate hypoglycemia. - MAO‑inhibitors and tricyclic antidepressants, which may alter glucose metabolism. - Diuretics, especially thiazides, that can affect potassium levels and insulin sensitivity.